venBio Partners LLC — 13F Holdings & Portfolio
CIK 1776382 · latest 13F-HR filed 2026-08-14
venBio Partners LLC manages $519.4M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PHVS (30.92%), PBLS (27.75%), ALMS (24.53%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions and exited 1; 3 existing positions rose in reported value and 1 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 100%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 12, 2026.
SUITE 595
SAN FRANCISCO, CA 94158-0008
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| GOODMAN, COREY, S. Control | MANAGING DIRECTOR since Jan 2018 | Less than 5% | Individual |
| Gaster, Richard, Samuel Control | MANAGING DIRECTOR since Apr 2020 | Less than 5% | Individual |
| Pezeshki, David Control | CFO & COO since Jun 2017 | Less than 5% | Individual |
| ROYSTON, AARON Control | MANAGING DIRECTOR since Apr 2019 | Less than 5% | Individual |
| VENBIO PARTNERS, L.P. Control | OWNER since Jan 2018 | 75% or more | Domestic Entity |
| ADELMAN, ROBERT Control Indirect owner via VENBIO PARTNERS, L.P. | LIMITED PARTNER since Jan 2018 | 25–50% | Individual |
| GOODMAN, COREY, S. Control Indirect owner via VENBIO PARTNERS, L.P. | LIMITED PARTNER since Jan 2018 | 25–50% | Individual |
| Gaster, Richard, Samuel Control Indirect owner via VENBIO PARTNERS, L.P. | LIMITED PARTNER since Jul 2021 | 25–50% | Individual |
| ROYSTON, AARON Control Indirect owner via VENBIO PARTNERS, L.P. | LIMITED PARTNER since Apr 2019 | 25–50% | Individual |
| VENBIO PARTNERS MANAGEMENT HOLDINGS GP, LLC Control Indirect owner via VENBIO PARTNERS, L.P. | GENERAL PARTNER since Jan 2018 | General partner, trustee or manager | Domestic Entity |
Ownership & leadership changes · 6 filings with changes since Sep 28, 2017
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedADELMAN, ROBERT · MANAGING DIRECTOR · Less than 5% · control person · listed since Jan 2018
- No longer listedDelhonte, Antoinette · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Aug 2021
- ChangedGaster, Richard, Samuel · title DIRECTOR → MANAGING DIRECTOR
- ChangedPezeshki, David · title CHIEF OPERATING OFFICER → CFO & COO
- ChangedROYSTON, AARON · title DIRECTOR → MANAGING DIRECTOR
- AddedDelhonte, Antoinette · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- AddedGaster, Richard, Samuel · LIMITED PARTNER · 25–50% · indirect via VENBIO PARTNERS, L.P. · control person
- ChangedPezeshki, David · title CHIEF FINANCIAL OFFICER → CHIEF OPERATING OFFICER
- AddedGaster, Richard, Samuel · DIRECTOR · Less than 5% · control person
- AddedROYSTON, AARON · DIRECTOR · Less than 5% · control person
- AddedROYSTON, AARON · LIMITED PARTNER · 25–50% · indirect via VENBIO PARTNERS, L.P. · control person
- ChangedADELMAN, ROBERT · indirect via VENBIO PARTNERS, L.P.: ownership 50–75% → 25–50%
- ChangedGOODMAN, COREY, S. · indirect via VENBIO PARTNERS, L.P.: ownership 50–75% → 25–50%
- AddedADELMAN, ROBERT · LIMITED PARTNER · 50–75% · indirect via VENBIO PARTNERS, L.P. · control person
- AddedGOODMAN, COREY, S. · LIMITED PARTNER · 50–75% · indirect via VENBIO PARTNERS, L.P. · control person
- AddedVENBIO PARTNERS MANAGEMENT HOLDINGS GP, LLC · GENERAL PARTNER · General partner, trustee or manager · indirect via VENBIO PARTNERS, L.P. · control person
- AddedVENBIO PARTNERS, L.P. · OWNER · 75% or more · control person
- ChangedADELMAN, ROBERT · ownership 25–50% → Less than 5%
- ChangedGOODMAN, COREY, S. · ownership 25–50% → Less than 5%
- ListedADELMAN, ROBERT · MANAGING DIRECTOR · 25–50% · control person
- ListedGOODMAN, COREY, S. · MANAGING DIRECTOR · 25–50% · control person
- ListedPezeshki, David · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PHARVARIS N V$29.5M +22.5%
- ALUMIS INC$27.7M +27.7%
- HARMONY BIOSCIENCES HLDGS IN$3.5M +25.5%
venBio Partners LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PHARVARIS N V | PHVS | N69605108 | $160.6M | 30.92% | 4,643,430 | SH |
| 2 | PARABILIS MEDICINES INC | PBLS | 698955101 | $144.1M | 27.75% | 5,266,697 | SH |
| 3 | ALUMIS INC | ALMS | 022307102 | $127.4M | 24.53% | 4,528,408 | SH |
| 4 | ACHIEVE LIFE SCIENCE INC | QUIT | 004468500 | $38.6M | 7.44% | 5,914,720 | SH |
| 5 | ALX ONCOLOGY HLDGS INC | ALXO | 00166B105 | $26.7M | 5.14% | 12,884,638 | SH |
| 6 | HARMONY BIOSCIENCES HLDGS IN | HRMY | 413197104 | $17.2M | 3.31% | 472,194 | SH |
| 7 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $4.7M | 0.91% | 337,697 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $519.4M | 7 | 0000905148-26-003741 |
| 2026-03-31 | 2026-05-15 | $280.6M | 6 | 0000905148-26-002409 |
| 2025-12-31 | 2026-02-17 | $216.3M | 6 | 0000905148-26-000841 |
| 2025-09-30 | 2025-11-14 | $176.4M | 6 | 0000905148-25-004034 |
SAN FRANCISCO, CA 94158